Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Standard BioTools Inc. (LAB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
2.8300+0.0900 (+3.28%)
At close: 04:00PM EDT
2.9500 +0.12 (+4.24%)
After hours: 05:29PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close2.7400
Open2.7300
Bid2.8100 x 800
Ask2.9500 x 1300
Day's Range2.7000 - 2.8698
52 Week Range0.9200 - 3.1600
Volume136,719
Avg. Volume260,250
Market Cap223.47M
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LAB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Standard BioTools Inc.
    Daily – Vickers Top Insider Picks for 09/26/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    13 hours agoArgus Research
View more
  • GlobeNewswire

    Standard BioTools Reports Second Quarter 2023 Financial Results

    Continued operational execution improves revenue growth, margin expansion, and expense reductionSOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) (“Standard BioTools”, or the “Company”), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the second quarter ended June 30, 2023. Selected Financial Results (Numbers in millions, except percentages)Quarter EndedJune 30, 2023 Qu

  • GlobeNewswire

    Standard BioTools to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced Company management will participate in the following investor conferences: Canaccord Genuity 43rd Annual Growth Conference: Michael Egholm, PhD, President and Chief Executive Officer, will participate in a fireside chat on Wednesday, August 9, 2023, at 3:30 p.m. ET.UBS MedTech, Tools and Geno

  • GlobeNewswire

    Standard BioTools Announces Conference Call and Webcast for Second Quarter 2023 Financial Results

    SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of the market. The Company’s management will host a conference call and webcast at 2:00 p.m. PT, 5:00 p.m. ET, on August 8, 2023, to discuss second quarter 2023 financial results and operation

Advertisement
Advertisement